30th Sep 2020 14:28
Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company - Gets approval from the US Food & Drug Administration for Alkindi Sprinkle as replacement therapy in paediatric patients with adrenocortical insufficiency. Alkindi Sprinkle is an oral, immediate-release formulation of hydrocortisone granules in capsules designed for children. Diurnal has partnered with Eton Pharmaceuticals for the commercialisation activities of Alkindi Sprinkle in US. Anticipates market launch of the product in fourth quarter of 2020.
Current stock price: 69.00 pence, up 4.5%
Year-to-date change: up more than 100% from 28p at December 31
By Tapan Panchal; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
DNL.L